A Phase 3 interventional study of ABT-450/r/ABT-267, ABT-333 and Ribavirin in Chronic Hepatitis C Infection, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-06-06.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing paritaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. paritaprevir · Hepatitis C, Chronic.
Among the 16 studies testing paritaprevir in Hepatitis C, Chronic, this one is the 5th largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 3, and was the 5th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 16 studies testing paritaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
paritaprevir: first FDA approval 2015 (TECHNIVIE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 10 · Phase 4 1
First in 2012; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 311 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 124 across the 16 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 5 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
83 studies in Hepatitis C, Chronic by AbbVie: none open now, none under way, none of them phase 3. Of 82 finished, 74 (90%) have results posted.
Among the 83 studies in Hepatitis C, Chronic by AbbVie, this one is the 17th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2013, is one of 40 in phase 3, and was the 13th registered.
AbbVie’s Hepatitis C, Chronic studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing paritaprevir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 83 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate the efficacy and safety of three experimental drugs compared with telaprevir (a licensed product) in people with hepatitis C virus infection who have not had treatment before.
The primary purpose of this study is to demonstrate that treatment with ABT-450/ritonavir (r)/ABT-267 and ABT-333 administered with or without ribavirin (RBV) has non-inferior efficacy compared to treatment with telaprevir and pegylated interferon alpha-2a (pegIFN) and RBV and to compare the safety of these regimens in treatment-naive hepatitis C virus (HCV) genotype (GT) 1a- and 1b-infected adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg twice daily (BID) and weight-based RBV for 12 weeks (3 direct-acting antivirals \[DAAs\] with RBV in GT1a)
Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin
Telaprevir (TPV) 750 mg every 8 hours (q8h) and pegIFN 180 µg/week and weight-based RBV (PR) for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a)
Drug: Ribavirin · Drug: Telaprevir · Drug: Pegylated Interferon alpha 2-a (PegIFN)
ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)
Drug: ABT-450/r/ABT-267, ABT-333 · Drug: Ribavirin
ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)
Drug: ABT-450/r/ABT-267, ABT-333
Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)
Drug: Ribavirin · Drug: Telaprevir · Drug: Pegylated Interferon alpha 2-a (PegIFN)
Drug pages: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir
Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Also known as: Viekira Pak, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Holkira Pak
Tablet
Film-coated tablet
Pre-filled syringe
Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after the last actual dose of active study drug
Mean Change From Baseline to the Final Treatment Visit in Short-Form 36 Version 2 Health Status Survey (SF-36V2) Mental Component Summary (MCS)
SF-36V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQoL) covering 2 summary measures: physical component summary (PCS) and MCS; it consists of 8 subscales. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Scoring is done for both MCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL).
Time frame: From Day 1 of treatment up to 12 weeks for Arms A, C and D and up to 24 or 48 weeks for Arms B and E
Mean Change From Baseline to the Final Treatment Visit in SF-36V2 Physical Component Summary (PCS)
SF-36V2 is a generic 36-item questionnaire measuring HRQoL covering 2 summary measures: PCS and MCS; it consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. Participants self-report on items in a subscale that have choices per item. Scoring is done for both PCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL).
Time frame: From Day 1 of treatment up to 12 weeks for Arms A, C and D and up to 24 or 48 weeks for Arms B and E
Percentage of Participants With SVR12 - Secondary Efficacy Analyses
The percentage of participants with sustained virologic response (plasma HCV RNA level \< LLOQ) 12 weeks after the last dose of study drug.
Time frame: 12 weeks after the last actual dose of active study drug
Percentage of Participants With Virologic Failure During Treatment
Participants in Arms A, C or D demonstrating any of the following were considered virologic failures and discontinued therapy: * Confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements of \>1 log10 IU/mL above nadir) at any time point during treatment * Failure to achieve HCV RNA \< LLOQ by Week 6 or * Confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) at any point after HCV RNA \< LLOQ during treatment after HCV RNA \< LLOQ. Participants in Arms B and E followed virologic stopping criteria described in the TPV Summary of Product Characteristics; they were considered virologic failures and discontinued therapy as follows: * HCV RNA \> 1000 IU/mL at Week 4 to Week 12, discontinue TPV and pegIFN and RBV * HCV RNA \> 1000 IU/mL at Week 12, discontinue pegIFN and RBV * Confirmed HCV RNA \> lower limit of detection (LLOD) at Week 24, discontinue pegIFN and RBV * Confirmed HCV RNA \> LLOD at Week 36, discontinue pegIFN and RBV.
Time frame: 12 weeks for Arms A, C and D and 24 weeks or 48 weeks for Arms B and E
Percentage of Participants With Post-treatment Relapse
Hepatitis C virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification (LLOQ) between the end of treatment and 24 weeks post treatment among participants completing treatment and with HCV RNA less than the LLOQ at the end of treatment.
Time frame: Within 24 weeks post treatment
Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24)
The percentage of participants with sustained virologic response (plasma HCV RNA level \< LLOQ) 24 weeks after the last dose of study drug.
Time frame: 24 weeks after the last actual dose of active study drug
| Milestone | Arm A: 3-DAA + RBV in GT1a | Arm B: TPV/PR in GT1a | Arm C: 3-DAA + RBV in GT1b | Arm D: 3-DAA in GT1b | Arm E: TPV/PR in GT1b |
|---|---|---|---|---|---|
| Started | 69 | 34 | 84 | 83 | 41 |
| Completed | 63 | 31 | 82 | 80 | 39 |
| Not completed | 6 | 3 | 2 | 3 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 4 | 1 | 1 | 2 | 0 |
| Withdrew: To enter another abbvie study | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrew consent | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 1 | 1 | 0 | 0 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid \[HCV RNA\] level less than the lower limit of quantitation \[\< LLOQ\]) 12 weeks after the last dose of study drug.
| percentage of participants | Arm A: 3-DAA + RBV in GT1a | Arm B: TPV/PR in GT1a | Arm C: 3-DAA + RBV in GT1b | Arm D: 3-DAA in GT1b | Arm E: TPV/PR in GT1b |
|---|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses | 97.1 | 82.4 | 98.8 | 97.6 | 78.0 |
SF-36V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQoL) covering 2 summary measures: physical component summary (PCS) and MCS; it consists of 8 subscales. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Scoring is done for both MCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL).
| units on a scale | Arm A: 3-DAA + RBV in GT1a | Arm B: TPV/PR in GT1a | Arm C: 3-DAA + RBV in GT1b | Arm D: 3-DAA in GT1b | Arm E: TPV/PR in GT1b |
|---|---|---|---|---|---|
| Mean Change From Baseline to the Final Treatment Visit in Short-Form 36 Version 2 Health Status Survey (SF-36V2) Mental Component Summary (MCS) | -4.2 ± 10.59 | -5.8 ± 12.18 | -0.3 ± 8.89 | -0.1 ± 7.73 | -6.4 ± 11.78 |
SF-36V2 is a generic 36-item questionnaire measuring HRQoL covering 2 summary measures: PCS and MCS; it consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. Participants self-report on items in a subscale that have choices per item. Scoring is done for both PCS subscale scores and summary scores; for each, the range is 0 (worst HRQoL) to 100 (best HRQoL).
| units on a scale | Arm A: 3-DAA + RBV in GT1a | Arm B: TPV/PR in GT1a | Arm C: 3-DAA + RBV in GT1b | Arm D: 3-DAA in GT1b | Arm E: TPV/PR in GT1b |
|---|---|---|---|---|---|
| Mean Change From Baseline to the Final Treatment Visit in SF-36V2 Physical Component Summary (PCS) | 0.5 ± 8.63 | -5.5 ± 8.26 | 0.4 ± 5.80 | 2.2 ± 4.34 | -5.5 ± 11.46 |
The percentage of participants with sustained virologic response (plasma HCV RNA level \< LLOQ) 12 weeks after the last dose of study drug.
| percentage of participants | Arm A: 3-DAA + RBV in GT1a | Arm B: TPV/PR in GT1a | Arm C: 3-DAA + RBV in GT1b | Arm D: 3-DAA in GT1b | Arm E: TPV/PR in GT1b |
|---|---|---|---|---|---|
| Percentage of Participants With SVR12 - Secondary Efficacy Analyses | 97.1 | 82.4 | 98.8 | 97.6 | 78.0 |
Participants in Arms A, C or D demonstrating any of the following were considered virologic failures and discontinued therapy: * Confirmed increase from nadir in HCV RNA (defined as 2 consecutive HCV RNA measurements of \>1 log10 IU/mL above nadir) at any time point during treatment * Failure to achieve HCV RNA \< LLOQ by Week 6 or * Confirmed HCV RNA ≥ LLOQ (defined as 2 consecutive HCV RNA measurements ≥ LLOQ) at any point after HCV RNA \< LLOQ during treatment after HCV RNA \< LLOQ. Participants in Arms B and E followed virologic stopping criteria described in the TPV Summary of Product Characteristics; they were considered virologic failures and discontinued therapy as follows: * HCV RNA \> 1000 IU/mL at Week 4 to Week 12, discontinue TPV and pegIFN and RBV * HCV RNA \> 1000 IU/mL at Week 12, discontinue pegIFN and RBV * Confirmed HCV RNA \> lower limit of detection (LLOD) at Week 24, discontinue pegIFN and RBV * Confirmed HCV RNA \> LLOD at Week 36, discontinue pegIFN and RBV.
| percentage of participants | Arm A: 3-DAA + RBV in GT1a | Arm B: TPV/PR in GT1a | Arm C: 3-DAA + RBV in GT1b | Arm D: 3-DAA in GT1b | Arm E: TPV/PR in GT1b |
|---|---|---|---|---|---|
| Percentage of Participants With Virologic Failure During Treatment | 2.9 | 5.9 | 0 | 1.2 | 12.2 |
Hepatitis C virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification (LLOQ) between the end of treatment and 24 weeks post treatment among participants completing treatment and with HCV RNA less than the LLOQ at the end of treatment.
| percentage of participants | Arm A: 3-DAA + RBV in GT1a | Arm B: TPV/PR in GT1a | Arm C: 3-DAA + RBV in GT1b | Arm D: 3-DAA in GT1b | Arm E: TPV/PR in GT1b |
|---|---|---|---|---|---|
| Percentage of Participants With Post-treatment Relapse | 0 | 0 | 1.2 | 0 | 6.3 |
The percentage of participants with sustained virologic response (plasma HCV RNA level \< LLOQ) 24 weeks after the last dose of study drug.
| percentage of participants | Arm A: 3-DAA + RBV in GT1a | Arm B: TPV/PR in GT1a | Arm C: 3-DAA + RBV in GT1b | Arm D: 3-DAA in GT1b | Arm E: TPV/PR in GT1b |
|---|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24) | 95.7 | 82.4 | 97.6 | 97.6 | 78.0 |
Collected over Adverse Events (AEs) collected from time of study drug administration until 30 days following discontinuation or completion of study drug administration, up to 96 weeks. Serious AEs collected from signing of informed consent until study completion.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3 DAA + RBV | — | 1/153 (0.7%) | 100/153 (65.4%) |
| 3 DAA | — | 0/83 (0%) | 29/83 (34.9%) |
| TPV + PEGIFN + RBV | — | 9/75 (12%) | 74/75 (98.7%) |
| Event | 3 DAA + RBV | 3 DAA | TPV + PEGIFN + RBV |
|---|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 0/153 | 0/83 | 2/75 |
| RETINOPATHYEye disorders | 0/153 | 0/83 | 1/75 |
| HAEMATOCHEZIAGastrointestinal disorders | 0/153 | 0/83 | 1/75 |
| CHEST PAINGeneral disorders | 0/153 | 0/83 | 1/75 |
| ABSCESS LIMBInfections and infestations | 0/153 | 0/83 | 1/75 |
| CELLULITISInfections and infestations | 0/153 | 0/83 | 1/75 |
| ACCIDENTAL OVERDOSEInjury, poisoning and procedural complications | 0/153 | 0/83 | 1/75 |
| COUGHRespiratory, thoracic and mediastinal disorders | 0/153 | 0/83 | 1/75 |
| TOXIC SKIN ERUPTIONSkin and subcutaneous tissue disorders | 0/153 | 0/83 | 1/75 |
| PROSTATE CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/153 | 0/83 | 0/75 |
| Event | 3 DAA + RBV | 3 DAA | TPV + PEGIFN + RBV |
|---|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 10/153 | 1/83 | 32/75 |
| NAUSEAGastrointestinal disorders | 32/153 | 7/83 | 30/75 |
| PRURITUSSkin and subcutaneous tissue disorders | 19/153 | 5/83 | 26/75 |
| FATIGUEGeneral disorders | 21/153 | 4/83 | 23/75 |
| HEADACHENervous system disorders | 41/153 | 16/83 | 23/75 |
| DECREASED APPETITEMetabolism and nutrition disorders | 6/153 | 1/83 | 17/75 |
| RASHSkin and subcutaneous tissue disorders | 12/153 | 0/83 | 17/75 |
| PYREXIAGeneral disorders | 4/153 | 2/83 | 16/75 |
| ASTHENIAGeneral disorders | 11/153 | 2/83 | 15/75 |
| NEUTROPENIABlood and lymphatic system disorders | 0/153 | 0/83 | 14/75 |
| Age, Continuous(years) | Arm A: 3-DAA + RBV in GT1a | Arm B: TPV/PR in GT1a | Arm C: 3-DAA + RBV in GT1b | Arm D: 3-DAA in GT1b | Arm E: TPV/PR in GT1b | Total |
|---|---|---|---|---|---|---|
| Mean | 46.1 ± 12.25 | 44.5 ± 14.10 | 46.2 ± 11.34 | 47.1 ± 11.33 | 45.9 ± 10.78 | 46.2 ± 11.75 |
| Age, Customized(participants) | Arm A: 3-DAA + RBV in GT1a | Arm B: TPV/PR in GT1a | Arm C: 3-DAA + RBV in GT1b | Arm D: 3-DAA in GT1b | Arm E: TPV/PR in GT1b | Total |
|---|---|---|---|---|---|---|
| < 55 years | 46 | 23 | 59 | 60 | 31 | 219 |
| >= 55 years | 23 | 11 | 25 | 23 | 10 | 92 |
| Sex: Female, Male(Participants) | Arm A: 3-DAA + RBV in GT1a | Arm B: TPV/PR in GT1a | Arm C: 3-DAA + RBV in GT1b | Arm D: 3-DAA in GT1b | Arm E: TPV/PR in GT1b | Total |
|---|---|---|---|---|---|---|
| Female | 21 | 17 | 46 | 43 | 24 | 151 |
| Male | 48 | 17 | 38 | 40 | 17 | 160 |
No study locations are listed for this record.
The record gives a start of Mar 2013, a primary completion of Nov 2014 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paritaprevir · Ritonavir · Ombitasvir · Dasabuvir · Ribavirin